LONDON—A promising new avenue in Alzheimer’s research that focuses on the eradication of brain plaque by the immune system has become the first investment for a $100 million fund dedicated to delivering new dementia drugs within a decade.
The Dementia Discovery Fund, set up last year with backing from the U.K. government and several of the world’s biggest pharmaceutical companies, has led a $29.5 million investment round to back research under way at San Francisco-based Alector LLC.